Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Clin Pharmacol Ther. 2021 Jul 23;110(3):733–740. doi: 10.1002/cpt.2337

Figure 1. Impact of SLCO1B1 rs4149056 genotype on risk of statin-induced myopathy and rhabdomyolysis in simvastatin, lovastatin, and atorvastatin users.

Figure 1.

Odds ratios (ORs) and 95% confidence intervals for risk of statin-induced myopathy and rhabdomyolysis with rs4149056 genotype are shown by statin type. ORs for TC and CC genotype are compared to TT genotype. In the entire cohort of statin users, a significantly increased risk of statin-induced myopathy and rhabdomyolysis was observed in individuals with the CC genotype. In the subset of simvastatin and lovastatin users, CC genotype was associated with significantly increased risk of statin-induced myopathy and rhabdomyolysis. In addition, TC genotype conferred a significantly increased risk in simvastatin users. In contrast, for atorvastatin users, no statistically significant risk for statin-induced myopathy and rhabdomyolysis was identified.